Version May 2024
Note: Premedication: To minimize radioactive iodine uptake by the thyroid gland, a thyroid blocking agent (eg, Lugol's solution) should be administered at least 24 hours prior to administration of iodine I-125 human serum albumin and continued for 1 or 2 weeks following administration.
Total blood and plasma volume detection: IV: 5 to 50 microcuries (0.185 to 1.85 MBq); maximum: if procedure needs repeated, do not exceed 200 microcuries (7.4 MBq) in any one week.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Central nervous system: Aseptic meningitis (chemical), hyperpyrexia
Hypersensitivity: Hypersensitivity reaction
There are no contraindications listed within the manufacturer's labeling.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other Warnings/Precautions:
• Appropriate use: Cisternography: Aseptic meningeal irritation and hyperpyrexia have been reported following use in cisternography. Iodine I-125 human serum albumin is not approved for use in cisternography.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, for injection:
Jeanatope: 18.5 megabecquerels (500 µCi)/0.5 mL [contains albumin (human), benzyl alcohol]
No
For IV administration. Radiopharmaceutical; use appropriate precautions for handling and disposal. Refer to manufacturer's labeling for complete administration recommendations and blood volume determination instructions.
Total blood and plasma volume detection: Radiopharmaceutical imaging agent used to detect total blood and plasma volume.
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
None known.
There are no known significant interactions.
Evaluate pregnancy status prior to administration (SNM 2010).
Iodine I-125 crosses the placenta and may permanently impair thyroid function of the fetus. If use is needed during pregnancy, an appropriate thyroid blocking agent is recommended.
Elective procedures should be delayed until the patient is no longer pregnant (SNM 2010).
Iodine I-125 is present in breast milk.
Evaluate lactation status prior to use (SNM 2010). Due to the potential for serious adverse reactions in the breastfed infant (including transient hypothyroidism), the manufacturer recommends breastfeeding be discontinued. Breastfeeding should not be initiated if exposure to iodine I-125 human serum albumin occurred during pregnancy.
Evaluate pregnancy and lactation status prior to use in patients of reproductive potential.
Metabolism: Decays by electron capture
Half-life elimination: Biologic half-life: ~14 days; Physical half-life: ~60 days
Metabolism: Decays by electron capture
Time to peak: Intravascular: 10 minutes; Extravascular: 2 to 4 days
Excretion: Urine (~98%); feces (~2%)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
